The role of soluble and cell-surface expressed 4-1BB ligand in patients with malignant hemopoietic disorders

被引:17
作者
Scholl, Nina [1 ]
Loibl, Julia [1 ]
Kremser, Andreas [1 ]
Liepert, Anja [1 ]
Grabrucker, Christine [1 ]
Salih, Helmut Rainer [2 ]
Kolb, Hans-Jochem [1 ,3 ]
Schmetzer, Helga Maria [1 ,3 ]
机构
[1] Univ Munich, Klinikum Grosshadern, Dept Med 3, D-81377 Munich, Germany
[2] Univ Tubingen, Dept Med 2, D-72074 Tubingen, Germany
[3] Helmholtz Ctr Munich, German Res Ctr Environm Health, CCG HCT, Munich, Germany
关键词
4-1BB (ligand); acute myeloid leukemias; myelodysplasia; lymphoma; dendritic cells; immuno modulation; ANTIGEN-PRESENTING CELLS; ACUTE MYELOID-LEUKEMIA; SERUM-FREE GENERATION; DENDRITIC CELLS; CD137; LIGAND; FAS LIGAND; BIOLOGICAL CHARACTERIZATION; PROGNOSTIC-FACTORS; MOLECULAR-CLONING; ACTIVATION;
D O I
10.1080/10428190802709453
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The TNFR family member 4-1BB and its ligand 4-1BBL are involved in the costimulation of T-cells and tumor-derived soluble (s)4-1BBL may influence the interaction of malignant cells with the immune system. Here, we report that cell-surface-expressed (c)4-1BBL can be expressed on mononuclear blood cells from patients with acute myeloid leukemia (AML) (n=35), myelodysplasia (n=5) or non-Hodgkin lymphoma (n=11) and can be coexpressed on varying proportions of lymphoid or myeloid malignant cells and on dendritic cells differentiated from AML-blasts. Direct correlations between c- and s4-1BBL were not found in the investigated cases. Up to now expression of 4-1BBL has not been described on primary myeloid malignant cells, but only on malignant cells of lymphoid or solid tumor origin or on tumor cell lines. With our work we further contribute to the understanding of the potential role of c/s4-1BBL in immune reactions and its influence on the interaction of tumor and immunoreactive cells.
引用
收藏
页码:427 / 436
页数:10
相关论文
共 39 条
[1]   MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF HUMAN 4-1BB AND ITS LIGAND [J].
ALDERSON, MR ;
SMITH, CA ;
TOUGH, TW ;
DAVISSMITH, T ;
ARMITAGE, RJ ;
FALK, B ;
ROUX, E ;
BAKER, E ;
SUTHERLAND, GR ;
DIN, WS ;
GOODWIN, RG .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (09) :2219-2227
[2]   MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF A MURINE LIGAND FOR CD40 [J].
ARMITAGE, RJ ;
FANSLOW, WC ;
STROCKBINE, L ;
SATO, TA ;
CLIFFORD, KN ;
MACDUFF, BM ;
ANDERSON, DM ;
GIMPEL, SD ;
DAVISSMITH, T ;
MALISZEWSKI, CR ;
CLARK, EA ;
SMITH, CA ;
GRABSTEIN, KH ;
COSMAN, D ;
SPRIGGS, MK .
NATURE, 1992, 357 (6373) :80-82
[3]   PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) :189-199
[4]   PROPOSALS FOR CLASSIFICATION OF ACUTE LEUKEMIAS [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1976, 33 (04) :451-&
[5]  
Chu NR, 1997, J IMMUNOL, V158, P3081
[6]  
DeBenedette MA, 1997, J IMMUNOL, V158, P551
[7]   MOLECULAR-CLONING OF A LIGAND FOR THE INDUCIBLE T-CELL GENE 4-1BB - A MEMBER OF AN EMERGING FAMILY OF CYTOKINES WITH HOMOLOGY TO TUMOR-NECROSIS-FACTOR [J].
GOODWIN, RG ;
DIN, WS ;
DAVISSMITH, T ;
ANDERSON, DM ;
GIMPEL, SD ;
SATO, TA ;
MALISZEWSKI, CR ;
BRANNAN, CI ;
COPELAND, NG ;
JENKINS, NA ;
FARRAH, T ;
ARMITAGE, RJ ;
FANSLOW, WC ;
SMITH, CA .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (10) :2631-2641
[8]   Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma [J].
Hentschel, N. ;
Krusch, M. ;
Kiener, P. A. ;
Kolb, H. J. ;
Salih, H. R. ;
Schmetzer, H. M. .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (02) :91-101
[9]   Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation [J].
Houtenbos, I ;
Westers, TM ;
Stam, AGM ;
de Gruijl, TD ;
Scheper, RJ ;
Ossenkoppele, GJ ;
van de Loosdrecht, AA .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2003, 52 (07) :455-462
[10]  
HURTADO JC, 1995, J IMMUNOL, V155, P3360